Pulmonx to Present at the Citi 2023 Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the Citi 2023 Healthcare Conference on March 2, 2023, at 10:15 AM PT / 1:15 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the Citi 2023 Healthcare Conference on March 2, 2023, at 10:15 AM PT / 1:15 PM ET. The event will be accessible via a live and archived webcast on the company’s Investors section of their website.
Pulmonx is known for its Zephyr® Endobronchial Valve and related systems used extensively in treating severe emphysema/COPD, with over 100,000 valves utilized in more than 25,000 patients worldwide.
Details
News Market Reaction – LUNG
The recorded move for LUNG in the trading session of this news was +1.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2023 Healthcare Conference in New York on Thursday, March 2, 2023, at 10:15 AM PT / 1:15 PM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.